Difficulty: Medium
Average Score: 74%
Practice
The mechanism of action of indirect-acting cholinomimetic agents is:
Correct answer
B
Rationale
The correct answer is B) Inhibition of the hydrolysis of endogenous acetylcholine. Indirect-acting cholinomimetic agents, such as acetylcholinesterase inhibitors, work by preventing the breakdown of acetylcholine, thereby increasing its availability at the receptor sites. This leads to prolonged stimulation of cholinergic receptors, resulting in enhanced cholinergic effects.
Option A, binding to and activation of muscarinic or nicotinic receptors, describes the mechanism of direct-acting cholinomimetic agents, not indirect-acting ones. Option C, stimulation of the action of acetylcholinesterase, is contradictory as these agents aim to inhibit acetylcholinesterase. Option D, releasing acetylcholine from storage sites, is not a typical mechanism of action for cholinomimetic agents.
In an educational context, understanding the mechanisms of action of pharmacological agents is crucial for safe and effective prescribing practices. Knowing how indirect-acting cholinomimetics work helps healthcare providers make informed decisions when selecting and monitoring these medications for patients across the lifespan. This knowledge is particularly essential in managing conditions such as myasthenia gravis, Alzheimer's disease, and certain types of poisoning.
Option A, binding to and activation of muscarinic or nicotinic receptors, describes the mechanism of direct-acting cholinomimetic agents, not indirect-acting ones. Option C, stimulation of the action of acetylcholinesterase, is contradictory as these agents aim to inhibit acetylcholinesterase. Option D, releasing acetylcholine from storage sites, is not a typical mechanism of action for cholinomimetic agents.
In an educational context, understanding the mechanisms of action of pharmacological agents is crucial for safe and effective prescribing practices. Knowing how indirect-acting cholinomimetics work helps healthcare providers make informed decisions when selecting and monitoring these medications for patients across the lifespan. This knowledge is particularly essential in managing conditions such as myasthenia gravis, Alzheimer's disease, and certain types of poisoning.